NEW
YORK, May 1, 2024 /CNW/ -- Strategic Advisory
for Leading Therapeutics Innovation Inc. (SALTI) is proud to
announce its official launch, poised to set a new standard in life
sciences consulting. Founded by Sherif Salti, a distinguished
leader in digital transformation within the life sciences sector,
SALTI is uniquely positioned to offer a differentiated partnership.
Drawing on his extensive track record of successful transformations
across the industry, the firm is designed to capitalize on emerging
opportunities and drive significant advancements in life sciences
commercialization. Expanding on the vision of its founder to
"Advance Medicine, Transform Lives," SALTI integrates a powerhouse
team with expertise in launch excellence, digital transformation,
scientific and medical advisory, advanced analytics, among
others.
Salti is an exceptional leader whose
profound expertise & unwavering dedication have been pivotal in
our transformation.
Ray Gomez, reflecting on his
partnership with Sherif Salti over the years that shaped
transformative strategies globally during his past collaborations
as Vice President of Worldwide Omnichannel Capabilities at Bristol
Myers Squibb, lauded his contributions: "Sherif Salti is an
exceptional leader whose profound expertise and unwavering
dedication have been pivotal in our transformation initiatives. His
strategic acumen and meticulous attention to detail have been
crucial in navigating complex challenges and delivering superior
outcomes."
In an industry propelled by rapid innovation and intricate
challenges, the strategic importance of specialty markets cannot be
overstated. Oncology, as the leading area of medicine costs
globally with a projected spend of $377
billion by 2027, highlights the critical need for
specialized expertise within life sciences organizations. Parallel
to this, the rise of emerging biopharmaceutical companies marks a
crucial industry trend. These agile and innovative entities often
find themselves hindered by the bureaucratic inertia typical of
larger, traditional options for strategic advisory partners. Such
companies, vital for driving sector-wide innovation, require
partners who mirror their agility and can adapt swiftly to changing
market dynamics.
SALTI, with its focused, agile teams, is uniquely equipped to
meet these needs. The new firm's approach delivers clear, strategic
insights without the burdensome overhead of conventional models,
fostering an environment where strategic planning seamlessly
transitions into impactful execution.
Sherif Salti elaborates on the firm's operational ethos: "Our
aim is to enhance our clients' ability to innovate autonomously. We
provide the roadmap and tools, but our goal is to empower clients
to lead their own advancements effectively. To that end, a
forthcoming roadmap from SALTI includes the introduction of
strategic capability 'accelerators'—tools and frameworks designed
to significantly enhance the efficiency and effectiveness of life
sciences capabilities, particularly for new product launches.
SALTI's partnership model is distinct in its aim to support
clients toward internalizing strategic capabilities. "Our focus is
on collaboration, not self-promotion. We ensure our clients, the
true pioneers of change, are front and center," Sherif Salti says.
"True value creation lies within — what makes our approach unique
is the enduring internal strategic growth we foster for our
clients."
About SALTI:
Strategic Advisory for Leading Therapeutics Innovation Inc. (SALTI)
is a management consulting firm dedicated to the life sciences
industry, specializing in commercial transformation, launch
excellence enablement, and evolving models of customer
engagement.
Media Contact:
media-relations@salti.co
Investor Contact:
investor-relations@salti.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/strategic-advisory-for-leading-therapeutics-innovation-inc-salti-announces-launch-to-set-new-standard-in-life-sciences-commercialization-management-consulting-302133187.html
SOURCE Strategic Advisory for Leading Therapeutics Innovation
Inc.